The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | WCLC 2023 highlights: FLAURA2 and EGFR exon20-targeting TKIs
Chul Kim, MD, MPH, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, shares his highlights from the 2023 World Conference on Lung Cancer 2023. The Phase III FLAURA2 clinical trial (NCT04035486) showed that osimertinib in combination with a platinum-based chemotherapy significantly improved progression-free survival (PFS) compared to osimertinib alone for patients with advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Dr Kim also comments on data relating to novel tyrosine kinase inhibitors (TKIs) such as high response rates to furmonertinib, an EGFR exon20-targeting TKI. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
